Notice of NIDA Participation in PAR-20-036 "Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)"
Dec 05 2019
Notice NIDA Participation PAR-20-036 Getting Zero: Understanding HIV Viral Suppression Transmission the United States R01 Clinical Trial Optional)" Notice Number: NOT-DA-20-016 Key Dates Release Date: December 5, 2019 Related Announcements PAR 20-036 Issued National Institute Drug Abuse NIDA) Purpose purpose this Notice to inform potential applicants the National Institute Drug Abuse NIDA) participating in PAR 20-036 "Getting Zero: Understanding HIV Viral Suppression Transmission the United States R01 Clinical Trial Optional)". following sections been updated reflect participation NIDA this FOA: Part 1. Overview Information Components Participating Organizations National Institute Allergy Infectious Diseases NIAID) National Institute Mental Health NIMH) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) Catalog Federal Domestic Assistance CFDA) Number(s) 93.855; 93.242; 93.865; 93.279 Part 2. Full Text Announcement Section I. Funding Opportunity Description NIDA interested the following areas research involving people use drugs PWUD) including key populations e.g., MSM, TW, FSW, HRH) where drug is common contributing HIV risk: Studies epidemiology HIV transmission care indicators testing, transmission networks, linkage care, engagement, suppression viral load) provide methods increasing accuracy speed providing data actionable data jurisdictional national population levels particular attention role drug use Studies provide timely evaluation HIV care, drug use, drug treatment, stratified substance and population-based factors such gender, sexual risk, race, age, geographic region. Epidemiology research understand long-term viral suppression the correlates predictors success relation patterns substance use, including injection practices. Studies provide timely evaluation HIV care, drug use, drug treatment, specific attention drug and structural features service delivery including variations policy environments, service availability, service integration financing prevention care services, including those related substance use. Research uncover novel correlates predictors initial sustained HIV viral suppression capitalizing information related contextual factors may affect suppression, including changes housing stability, transitions and of incarceration other kinds institutionalization supervision e.g., drug court, probation, parole, foster care). Research regarding role participation syringe service programs SSPs) viral suppression on participation services provide pathways viral suppression e.g., HIV testing, referral care, care adherence). Research focuses the impact stigma access utilization care success preventing treating HIV, attention stigmas related drug e.g., drug user self-stigma, stigma anticipated or enacted providers, stigma among providers around serving drug users). Implementation science research combines knowledge derived epidemiology, data science or modeling on-the-ground experiences improve viral suppression. Such research focus testing approaches identify diagnose hard-to-reach populations, strategies improve service delivery, strategies targeting structural and/or systems-level barriers service delivery ART adherence substance using populations e.g. socio-economic marginalization, stigma, incarceration, poor access substance treatment, destitution. Partnerships care implementers community key elements these studies. addition the methods noted PAR-20-036 https://grants.nih.gov/grants/guide/pa-files/PAR-20-036.html, NIDA encourages application innovative approaches including system dynamics modeling geographic information systems. of multiple sources data sources encouraged including strategies link methodologically comparable datasets utilize readily available public and administrative data. Part 2. Section VII. Agency Contacts Scientific/Research Contact(s) Richard A. Jenkins, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-1923 Email: firstname.lastname@example.org Financial/Grants Management Contact(s) Pam Fleming National Institute Drug Abuse NIDA) Telephone: 301-480-1159 Email: email@example.com other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Richard A. Jenkins, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-1923 Email: firstname.lastname@example.org